Enzymatica AB (publ) (STO:ENZY)

Market Cap	442.99M +37.8%
Revenue (ttm)	52.73M +19.2%
Net Income	-54.14M
EPS	-0.22
Shares Out	242.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,282
Average Volume	82,387
Open	1.795
Previous Close	1.825
Day's Range	1.705 - 1.900
52-Week Range	1.430 - 5.450
Beta	0.35
RSI	41.91
Earnings Date	Feb 18, 2026

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ENZY

Financial Performance

In 2024, Enzymatica AB's revenue was 45.58 million, a decrease of -10.47% compared to the previous year's 50.90 million. Losses were -53.18 million, 6.94% more than in 2023.